ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Overactive Bladder Drug Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-34F7013
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Overactive Bladder Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Global Overactive Bladder Drug Market Research Report 2025

Code: QYRE-Auto-34F7013
Report
August 2025
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astellas Pharma Inc. (Japan)
Pfizer Inc. (US)
Teva Pharmaceutical Industries Limited (Israel)
Allergan Plc (Ireland)
Medtronic plc (Ireland)
Mylan N.V. (US)
Endo International plc (Ireland)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
Sanofi (France)
Apotex Inc. (Canada)
Cogentix Medical, Inc. (US)
Aurobindo Pharma Limited (India)

Overactive Bladder Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Overactive Bladder Drug Market

Overactive Bladder Drug Market

The global market for Overactive Bladder Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Overactive Bladder Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Overactive Bladder Drug.
The Overactive Bladder Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Overactive Bladder Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Overactive Bladder Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Overactive Bladder Drug Market Report

Report Metric Details
Report Name Overactive Bladder Drug Market
CAGR 5%
Segment by Type
  • Anticholinergics
  • Solifenacin
  • Oxybutynin
  • Darifenacin
  • Fesoterodine
  • Tolterodine
  • Trospium
  • Others
Segment by Application
  • Idiopathic Bladder Overactivity
  • Neurogenic Bladder Overactivity
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Astellas Pharma, Inc. (Japan), Pfizer, Inc. (US), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (US), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Apotex, Inc. (Canada), Cogentix Medical, Inc. (US), Aurobindo Pharma Limited (India)
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Overactive Bladder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Overactive Bladder Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Overactive Bladder Drug Market report?

Ans: The main players in the Overactive Bladder Drug Market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (US), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (US), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Apotex, Inc. (Canada), Cogentix Medical, Inc. (US), Aurobindo Pharma Limited (India)

What are the Application segmentation covered in the Overactive Bladder Drug Market report?

Ans: The Applications covered in the Overactive Bladder Drug Market report are Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity

What are the Type segmentation covered in the Overactive Bladder Drug Market report?

Ans: The Types covered in the Overactive Bladder Drug Market report are Anticholinergics, Solifenacin, Oxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium, Others

1 Overactive Bladder Drug Market Overview
1.1 Product Definition
1.2 Overactive Bladder Drug by Type
1.2.1 Global Overactive Bladder Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Anticholinergics
1.2.3 Solifenacin
1.2.4 Oxybutynin
1.2.5 Darifenacin
1.2.6 Fesoterodine
1.2.7 Tolterodine
1.2.8 Trospium
1.2.9 Others
1.3 Overactive Bladder Drug by Application
1.3.1 Global Overactive Bladder Drug Market Value by Application (2024 VS 2031)
1.3.2 Idiopathic Bladder Overactivity
1.3.3 Neurogenic Bladder Overactivity
1.4 Global Overactive Bladder Drug Market Size Estimates and Forecasts
1.4.1 Global Overactive Bladder Drug Revenue 2020-2031
1.4.2 Global Overactive Bladder Drug Sales 2020-2031
1.4.3 Global Overactive Bladder Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Overactive Bladder Drug Market Competition by Manufacturers
2.1 Global Overactive Bladder Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Overactive Bladder Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Overactive Bladder Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Overactive Bladder Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Overactive Bladder Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Overactive Bladder Drug, Product Type & Application
2.7 Global Key Manufacturers of Overactive Bladder Drug, Date of Enter into This Industry
2.8 Global Overactive Bladder Drug Market Competitive Situation and Trends
2.8.1 Global Overactive Bladder Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Overactive Bladder Drug Players Market Share by Revenue
2.8.3 Global Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Overactive Bladder Drug Market Scenario by Region
3.1 Global Overactive Bladder Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Overactive Bladder Drug Sales by Region: 2020-2031
3.2.1 Global Overactive Bladder Drug Sales by Region: 2020-2025
3.2.2 Global Overactive Bladder Drug Sales by Region: 2026-2031
3.3 Global Overactive Bladder Drug Revenue by Region: 2020-2031
3.3.1 Global Overactive Bladder Drug Revenue by Region: 2020-2025
3.3.2 Global Overactive Bladder Drug Revenue by Region: 2026-2031
3.4 North America Overactive Bladder Drug Market Facts & Figures by Country
3.4.1 North America Overactive Bladder Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Overactive Bladder Drug Sales by Country (2020-2031)
3.4.3 North America Overactive Bladder Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Overactive Bladder Drug Market Facts & Figures by Country
3.5.1 Europe Overactive Bladder Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Overactive Bladder Drug Sales by Country (2020-2031)
3.5.3 Europe Overactive Bladder Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Overactive Bladder Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Overactive Bladder Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Overactive Bladder Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Overactive Bladder Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Overactive Bladder Drug Market Facts & Figures by Country
3.7.1 Latin America Overactive Bladder Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Overactive Bladder Drug Sales by Country (2020-2031)
3.7.3 Latin America Overactive Bladder Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Overactive Bladder Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Overactive Bladder Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Overactive Bladder Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Overactive Bladder Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Overactive Bladder Drug Sales by Type (2020-2031)
4.1.1 Global Overactive Bladder Drug Sales by Type (2020-2025)
4.1.2 Global Overactive Bladder Drug Sales by Type (2026-2031)
4.1.3 Global Overactive Bladder Drug Sales Market Share by Type (2020-2031)
4.2 Global Overactive Bladder Drug Revenue by Type (2020-2031)
4.2.1 Global Overactive Bladder Drug Revenue by Type (2020-2025)
4.2.2 Global Overactive Bladder Drug Revenue by Type (2026-2031)
4.2.3 Global Overactive Bladder Drug Revenue Market Share by Type (2020-2031)
4.3 Global Overactive Bladder Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Overactive Bladder Drug Sales by Application (2020-2031)
5.1.1 Global Overactive Bladder Drug Sales by Application (2020-2025)
5.1.2 Global Overactive Bladder Drug Sales by Application (2026-2031)
5.1.3 Global Overactive Bladder Drug Sales Market Share by Application (2020-2031)
5.2 Global Overactive Bladder Drug Revenue by Application (2020-2031)
5.2.1 Global Overactive Bladder Drug Revenue by Application (2020-2025)
5.2.2 Global Overactive Bladder Drug Revenue by Application (2026-2031)
5.2.3 Global Overactive Bladder Drug Revenue Market Share by Application (2020-2031)
5.3 Global Overactive Bladder Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Astellas Pharma, Inc. (Japan)
6.1.1 Astellas Pharma, Inc. (Japan) Company Information
6.1.2 Astellas Pharma, Inc. (Japan) Description and Business Overview
6.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Portfolio
6.1.5 Astellas Pharma, Inc. (Japan) Recent Developments/Updates
6.2 Pfizer, Inc. (US)
6.2.1 Pfizer, Inc. (US) Company Information
6.2.2 Pfizer, Inc. (US) Description and Business Overview
6.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer, Inc. (US) Overactive Bladder Drug Product Portfolio
6.2.5 Pfizer, Inc. (US) Recent Developments/Updates
6.3 Teva Pharmaceutical Industries Limited (Israel)
6.3.1 Teva Pharmaceutical Industries Limited (Israel) Company Information
6.3.2 Teva Pharmaceutical Industries Limited (Israel) Description and Business Overview
6.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Portfolio
6.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Developments/Updates
6.4 Allergan, Plc (Ireland)
6.4.1 Allergan, Plc (Ireland) Company Information
6.4.2 Allergan, Plc (Ireland) Description and Business Overview
6.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Allergan, Plc (Ireland) Overactive Bladder Drug Product Portfolio
6.4.5 Allergan, Plc (Ireland) Recent Developments/Updates
6.5 Medtronic plc (Ireland)
6.5.1 Medtronic plc (Ireland) Company Information
6.5.2 Medtronic plc (Ireland) Description and Business Overview
6.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Medtronic plc (Ireland) Overactive Bladder Drug Product Portfolio
6.5.5 Medtronic plc (Ireland) Recent Developments/Updates
6.6 Mylan N.V. (US)
6.6.1 Mylan N.V. (US) Company Information
6.6.2 Mylan N.V. (US) Description and Business Overview
6.6.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Mylan N.V. (US) Overactive Bladder Drug Product Portfolio
6.6.5 Mylan N.V. (US) Recent Developments/Updates
6.7 Endo International plc (Ireland)
6.7.1 Endo International plc (Ireland) Company Information
6.7.2 Endo International plc (Ireland) Description and Business Overview
6.7.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Endo International plc (Ireland) Overactive Bladder Drug Product Portfolio
6.7.5 Endo International plc (Ireland) Recent Developments/Updates
6.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
6.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Information
6.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Description and Business Overview
6.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Portfolio
6.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments/Updates
6.9 Sanofi (France)
6.9.1 Sanofi (France) Company Information
6.9.2 Sanofi (France) Description and Business Overview
6.9.3 Sanofi (France) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sanofi (France) Overactive Bladder Drug Product Portfolio
6.9.5 Sanofi (France) Recent Developments/Updates
6.10 Apotex, Inc. (Canada)
6.10.1 Apotex, Inc. (Canada) Company Information
6.10.2 Apotex, Inc. (Canada) Description and Business Overview
6.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Apotex, Inc. (Canada) Overactive Bladder Drug Product Portfolio
6.10.5 Apotex, Inc. (Canada) Recent Developments/Updates
6.11 Cogentix Medical, Inc. (US)
6.11.1 Cogentix Medical, Inc. (US) Company Information
6.11.2 Cogentix Medical, Inc. (US) Description and Business Overview
6.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Portfolio
6.11.5 Cogentix Medical, Inc. (US) Recent Developments/Updates
6.12 Aurobindo Pharma Limited (India)
6.12.1 Aurobindo Pharma Limited (India) Company Information
6.12.2 Aurobindo Pharma Limited (India) Description and Business Overview
6.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Portfolio
6.12.5 Aurobindo Pharma Limited (India) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Overactive Bladder Drug Industry Chain Analysis
7.2 Overactive Bladder Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Overactive Bladder Drug Production Mode & Process Analysis
7.4 Overactive Bladder Drug Sales and Marketing
7.4.1 Overactive Bladder Drug Sales Channels
7.4.2 Overactive Bladder Drug Distributors
7.5 Overactive Bladder Drug Customer Analysis
8 Overactive Bladder Drug Market Dynamics
8.1 Overactive Bladder Drug Industry Trends
8.2 Overactive Bladder Drug Market Drivers
8.3 Overactive Bladder Drug Market Challenges
8.4 Overactive Bladder Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Astellas Pharma Inc. (Japan)
Pfizer Inc. (US)
Teva Pharmaceutical Industries Limited (Israel)
Allergan Plc (Ireland)
Medtronic plc (Ireland)
Mylan N.V. (US)
Endo International plc (Ireland)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
Sanofi (France)
Apotex Inc. (Canada)
Cogentix Medical, Inc. (US)
Aurobindo Pharma Limited (India)
List of Tables
 Table 1. Global Overactive Bladder Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Overactive Bladder Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Overactive Bladder Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Overactive Bladder Drug Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Overactive Bladder Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Overactive Bladder Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Overactive Bladder Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Overactive Bladder Drug Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Overactive Bladder Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Overactive Bladder Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Overactive Bladder Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Overactive Bladder Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Overactive Bladder Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Overactive Bladder Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Overactive Bladder Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Overactive Bladder Drug Sales by Region (2020-2025) & (K Units)
 Table 18. Global Overactive Bladder Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Overactive Bladder Drug Sales by Region (2026-2031) & (K Units)
 Table 20. Global Overactive Bladder Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Overactive Bladder Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Overactive Bladder Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Overactive Bladder Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Overactive Bladder Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Overactive Bladder Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Overactive Bladder Drug Sales by Country (2020-2025) & (K Units)
 Table 27. North America Overactive Bladder Drug Sales by Country (2026-2031) & (K Units)
 Table 28. North America Overactive Bladder Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Overactive Bladder Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Overactive Bladder Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Overactive Bladder Drug Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Overactive Bladder Drug Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Overactive Bladder Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Overactive Bladder Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Overactive Bladder Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Overactive Bladder Drug Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Overactive Bladder Drug Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Overactive Bladder Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Overactive Bladder Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Overactive Bladder Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Overactive Bladder Drug Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Overactive Bladder Drug Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Overactive Bladder Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Overactive Bladder Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Overactive Bladder Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Overactive Bladder Drug Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Overactive Bladder Drug Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Overactive Bladder Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Overactive Bladder Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Overactive Bladder Drug Sales (K Units) by Type (2020-2025)
 Table 51. Global Overactive Bladder Drug Sales (K Units) by Type (2026-2031)
 Table 52. Global Overactive Bladder Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Overactive Bladder Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Overactive Bladder Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Overactive Bladder Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Overactive Bladder Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Overactive Bladder Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Overactive Bladder Drug Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Overactive Bladder Drug Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Overactive Bladder Drug Sales (K Units) by Application (2020-2025)
 Table 61. Global Overactive Bladder Drug Sales (K Units) by Application (2026-2031)
 Table 62. Global Overactive Bladder Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Overactive Bladder Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Overactive Bladder Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Overactive Bladder Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Overactive Bladder Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Overactive Bladder Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Overactive Bladder Drug Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Overactive Bladder Drug Price (USD/Unit) by Application (2026-2031)
 Table 70. Astellas Pharma, Inc. (Japan) Company Information
 Table 71. Astellas Pharma, Inc. (Japan) Description and Business Overview
 Table 72. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product
 Table 74. Astellas Pharma, Inc. (Japan) Recent Developments/Updates
 Table 75. Pfizer, Inc. (US) Company Information
 Table 76. Pfizer, Inc. (US) Description and Business Overview
 Table 77. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Pfizer, Inc. (US) Overactive Bladder Drug Product
 Table 79. Pfizer, Inc. (US) Recent Developments/Updates
 Table 80. Teva Pharmaceutical Industries Limited (Israel) Company Information
 Table 81. Teva Pharmaceutical Industries Limited (Israel) Description and Business Overview
 Table 82. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product
 Table 84. Teva Pharmaceutical Industries Limited (Israel) Recent Developments/Updates
 Table 85. Allergan, Plc (Ireland) Company Information
 Table 86. Allergan, Plc (Ireland) Description and Business Overview
 Table 87. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Allergan, Plc (Ireland) Overactive Bladder Drug Product
 Table 89. Allergan, Plc (Ireland) Recent Developments/Updates
 Table 90. Medtronic plc (Ireland) Company Information
 Table 91. Medtronic plc (Ireland) Description and Business Overview
 Table 92. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Medtronic plc (Ireland) Overactive Bladder Drug Product
 Table 94. Medtronic plc (Ireland) Recent Developments/Updates
 Table 95. Mylan N.V. (US) Company Information
 Table 96. Mylan N.V. (US) Description and Business Overview
 Table 97. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Mylan N.V. (US) Overactive Bladder Drug Product
 Table 99. Mylan N.V. (US) Recent Developments/Updates
 Table 100. Endo International plc (Ireland) Company Information
 Table 101. Endo International plc (Ireland) Description and Business Overview
 Table 102. Endo International plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Endo International plc (Ireland) Overactive Bladder Drug Product
 Table 104. Endo International plc (Ireland) Recent Developments/Updates
 Table 105. Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Information
 Table 106. Hisamitsu Pharmaceutical Co., Inc. (Japan) Description and Business Overview
 Table 107. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product
 Table 109. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments/Updates
 Table 110. Sanofi (France) Company Information
 Table 111. Sanofi (France) Description and Business Overview
 Table 112. Sanofi (France) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Sanofi (France) Overactive Bladder Drug Product
 Table 114. Sanofi (France) Recent Developments/Updates
 Table 115. Apotex, Inc. (Canada) Company Information
 Table 116. Apotex, Inc. (Canada) Description and Business Overview
 Table 117. Apotex, Inc. (Canada) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Apotex, Inc. (Canada) Overactive Bladder Drug Product
 Table 119. Apotex, Inc. (Canada) Recent Developments/Updates
 Table 120. Cogentix Medical, Inc. (US) Company Information
 Table 121. Cogentix Medical, Inc. (US) Description and Business Overview
 Table 122. Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product
 Table 124. Cogentix Medical, Inc. (US) Recent Developments/Updates
 Table 125. Aurobindo Pharma Limited (India) Company Information
 Table 126. Aurobindo Pharma Limited (India) Description and Business Overview
 Table 127. Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product
 Table 129. Aurobindo Pharma Limited (India) Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Overactive Bladder Drug Distributors List
 Table 133. Overactive Bladder Drug Customers List
 Table 134. Overactive Bladder Drug Market Trends
 Table 135. Overactive Bladder Drug Market Drivers
 Table 136. Overactive Bladder Drug Market Challenges
 Table 137. Overactive Bladder Drug Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Overactive Bladder Drug
 Figure 2. Global Overactive Bladder Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Overactive Bladder Drug Market Share by Type: 2024 & 2031
 Figure 4. Anticholinergics Product Picture
 Figure 5. Solifenacin Product Picture
 Figure 6. Oxybutynin Product Picture
 Figure 7. Darifenacin Product Picture
 Figure 8. Fesoterodine Product Picture
 Figure 9. Tolterodine Product Picture
 Figure 10. Trospium Product Picture
 Figure 11. Others Product Picture
 Figure 12. Global Overactive Bladder Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 13. Global Overactive Bladder Drug Market Share by Application: 2024 & 2031
 Figure 14. Idiopathic Bladder Overactivity
 Figure 15. Neurogenic Bladder Overactivity
 Figure 16. Global Overactive Bladder Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Overactive Bladder Drug Market Size (2020-2031) & (US$ Million)
 Figure 18. Global Overactive Bladder Drug Sales (2020-2031) & (K Units)
 Figure 19. Global Overactive Bladder Drug Average Price (USD/Unit) & (2020-2031)
 Figure 20. Overactive Bladder Drug Report Years Considered
 Figure 21. Overactive Bladder Drug Sales Share by Manufacturers in 2024
 Figure 22. Global Overactive Bladder Drug Revenue Share by Manufacturers in 2024
 Figure 23. Global 5 and 10 Largest Overactive Bladder Drug Players: Market Share by Revenue in Overactive Bladder Drug in 2024
 Figure 24. Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 25. Global Overactive Bladder Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 26. North America Overactive Bladder Drug Sales Market Share by Country (2020-2031)
 Figure 27. North America Overactive Bladder Drug Revenue Market Share by Country (2020-2031)
 Figure 28. U.S. Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Canada Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Europe Overactive Bladder Drug Sales Market Share by Country (2020-2031)
 Figure 31. Europe Overactive Bladder Drug Revenue Market Share by Country (2020-2031)
 Figure 32. Germany Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. France Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. U.K. Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Italy Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Russia Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Asia Pacific Overactive Bladder Drug Sales Market Share by Region (2020-2031)
 Figure 38. Asia Pacific Overactive Bladder Drug Revenue Market Share by Region (2020-2031)
 Figure 39. China Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Japan Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. South Korea Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. India Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Australia Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Taiwan Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Indonesia Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Thailand Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Malaysia Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Philippines Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America Overactive Bladder Drug Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Overactive Bladder Drug Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa Overactive Bladder Drug Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Overactive Bladder Drug Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. UAE Overactive Bladder Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of Overactive Bladder Drug by Type (2020-2031)
 Figure 60. Global Revenue Market Share of Overactive Bladder Drug by Type (2020-2031)
 Figure 61. Global Overactive Bladder Drug Price (USD/Unit) by Type (2020-2031)
 Figure 62. Global Sales Market Share of Overactive Bladder Drug by Application (2020-2031)
 Figure 63. Global Revenue Market Share of Overactive Bladder Drug by Application (2020-2031)
 Figure 64. Global Overactive Bladder Drug Price (USD/Unit) by Application (2020-2031)
 Figure 65. Overactive Bladder Drug Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Overactive Bladder OAB Bionic Drug Market Research Report 2025
Global Bladder Diseases Drug Market Research Report 2025
Global Urinary Incontinence Drug Market Research Report 2025
Urinary Incontinence Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Urinary Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Non Muscle Invasive Bladder Cancer Treatment Market Research Report 2024
Urinary System Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Urinary Tract Infection Therapeutics Market Research Report 2025
Global Urinary Antispasodics Market Research Report 2024
Global Female Urinary Incontinence Treatment Market Research Report 2024
Diuretics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diuretic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Over the Counter Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Urinary Tract Infection UTI Medications Market Research Report 2025
Global Urinary Tract Cancer Treatment Market Research Report 2024
Global Drugs of Abuse Testing Market Research Report 2024
Incontinence Treatment System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Over the Counter Diagnostic Products Market Research Report 2024
Global Chronic Kidney Disease Drugs Market Research Report 2025
Global Cardiovascular Disease Nursing Drugs Market Research Report 2025

RELATED REPORTS

Global Long-Acting HIV-1 Inhibitors Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19B19893
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Methylphenidate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30B3636
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Soliris Intravenous Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3H1702
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mouth Ulcers Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13C3384
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions